Maintenance of angiogenesis inhibition with aflibercept after progression to bevacizumab in metastatic colorectal cancer: real life study in the Valencian community
Clin. transl. oncol. (Print)
; 25(5): 1455-1462, mayo 2023. graf
Artigo
em Inglês
| IBECS
| ID: ibc-219528
Biblioteca responsável:
ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
Introduction The second-line chemotherapy in metastatic colorectal cancer (mCRC) with FOLFIRI-aflibercept demonstrated an increase in survival compared with FOLFIRI in patients previously treated with oxaliplatin-based regimens. Few data are available in patients treated previously with bevacizumab. Our objective is to evaluate the efficacy and safety of FOLFIRI-aflibercept in second-line treatment in patients who have previously received bevacizumab. Patients and methods This is a observational, retrospective study of patients with mCRC treated with FOLFIRI-aflibercept in 2nd line in eight hospitals in the Valencian Community. Survival, response, and toxicity were analyzed. Result 122 patients with a median age of 61 years were included. 89% of patients had PS 01. The median of PFS (progression free survival) and OS (overall survival) was 5.45 (95% CI 4.746.15 months) and 10.15 (95% CI 7.4712.82 months), respectively. Disease control rate 59.8%. The most common grade 34 adverse events were neutropenia (13,1%) and asthenia (9%). The presence of hypertension during treatment with FOLFIRI-aflibercept was associated with a survival benefit. Median of OS was 14.45 (95% CI 11.5817.32) in patients with hypertension vs 7.78 (95% CI 5.0210.54) in patients without hypertension (p = .001). Our results suggest that the presence of PS 0, primary tumor surgery, metachronous metastases, and the presence of only 1 metastatic location, are favorable prognostic factors associated with better OS. Conclusions Our results confirm the value of maintaining angiogenesis inhibition with FOLFIRI-aflibercept in mCRC after progression to a first-line treatment with bevacizumab. The development of hypertension during treatment is a possible predictive marker of response (AU)
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Neoplasias Colorretais
/
Hipertensão
Limite:
Humanos
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2023
Tipo de documento:
Artigo
Instituição/País de afiliação:
Fundación Instituto Valenciano de Oncología/Spain
/
Hospital Arnau de Vilanova/Spain
/
Hospital General Universitario de Valencia/Spain
/
Hospital Provincial de Castellón/Spain
/
Hospital Universitario Doctor Peset de Valencia/Spain
/
Hospital Universitario de La Ribera/Spain
/
Hospital Universitario y Politécnico La Fe/Spain
/
Hospital de Sagunto/Spain
/
Universitat de València/Spain